Three key hurdles restraining the growth of the tissue engineering field
The interdisciplinary field of regenerative medicine – comprised of tissue engineering (TE), cell therapy (CT), and gene therapy (GT) – is growing rapidly,...
Mr. Lev Gerlovin has more than 20 years of consulting experience across strategic planning, litigation, and policy spheres. His recent focus has been in leading strategy engagements for a diverse set of clients, including major pharmaceutical and biotechnology manufacturers, distributors, health plan providers, and industry groups.
Mr. Gerlovin has managed projects spanning commercial strategy, pricing and market access, product design and optimization, product launch, portfolio lifecycle management, channels and distribution, sales and marketing effectiveness, and organizational design. He has broad therapeutic category experience, particularly in diabetes, endocrinology, neurology, psychiatry, hematology, oncology, immunology, rare diseases, and cell and gene therapy. He leads CRA’s Life Sciences 2030 Idea Leadership Platform.